Staff Reports
Director Sara Carter told Greg Kelly on Newsmax that President Trump’s drug strategy is working. That’s a bold claim. It deserves applause if true, but it also deserves a microscope. Below is the interview clip and a plain‑spoken look at what “working” really means for drug policy, fentanyl interdiction, border security, and overdose deaths.
What the Trump drug strategy says it does
The administration’s plan is simple to say: stop the supply, seal the border, punish traffickers, and expand treatment. Director Sara Carter, now confirmed to lead the Office of National Drug Control Policy (ONDCP), has been selling that mix on TV and at briefings. Supply‑side measures — big seizures, pressure on precursor chemical flows, and tougher interdiction at ports and land crossings — are the backbone of the message.
The numbers cited — real, but with big asterisks
Federal agencies report massive seizures of fentanyl pills and powder and say interdiction is up. Provisional CDC counts show recent declines in overdose deaths after earlier spikes. That’s the evidence the administration points to when it says the strategy is working. But don’t break out the victory banner yet. Provisional data are subject to revision, trends vary by state, and causal proof that these policies caused the declines is thin so far. GAO and public‑health analysts warn the drug market is complex; one month of good news doesn’t end a crisis.
Seizures, potency, and the lab problem
Seizure totals make for great headlines — multi‑million‑pill and multi‑thousand‑pound busts do catch attention. Still, how those seizures change the real supply on the street depends on cartel reactions, shift in routes, and lab testing. For a true answer, we need transparent, dated seizure logs, DEA and CBP trend tables, and the CDC provisional dashboard pulled for the exact places Director Carter referenced. In plain talk: show the receipts.
Politics, credibility, and the next steps
Critics questioned Director Carter’s background at confirmation. Fine — credentials matter. But what matters more is results. If the strategy is saving lives, the administration should make the data easy to verify. Ask ONDCP for the exact metrics behind the “working” claim. Ask independent epidemiologists and state health officials whether declines look real and sustained. If you’re on Team Trump, cheer responsibly. If you’re a skeptic, demand proof instead of partisan talking points.
Bottom line: there are promising signs — fewer provisional overdose deaths in federal tallies and headline‑grabbing seizures give the administration reason to brag. But public policy should be judged by durable results and transparency, not by TV soundbites. President Trump’s strategy may be moving the needle. That’s good news. Now make it durable. Show the data. Keep seizing drugs. Save more lives.
